Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Pituitary Neoplasms 7Pituitary ACTH Hypersecretion 3Acromegaly 2Recurrence 1Prostatic Neoplasms 1Prolactinoma 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Brain Neoplasms 1Adrenocortical Hyperfunction 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

atezolizumab 2Trastuzumab 2Magnetic Resonance Spectroscopy 2vandetanib 1tivozanib 1tipifarnib 1temsirolimus 1romidepsin 1pembrolizumab 1pasireotide 1methyl hydroxyethyl cellulose 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entinostat 1Walking 1Vinorelbine 1Suramin 1Standard of Care 1Specimen Handling 1Sirolimus 1Ritonavir 1Respiratory Therapy 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Cabergoline × Endocrine × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡